Free shipping on all orders over $ 500

Pyroxamide

Cat. No. M3243

All AbMole products are for research use only, cannot be used for human consumption.

Pyroxamide Structure
Synonym:

NSC-696085

Size Price Availability Quantity
5mg USD 55  USD55 In stock
10mg USD 95  USD95 In stock
25mg USD 200  USD200 In stock
50mg USD 330  USD330 In stock
100mg USD 550  USD550 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pyroxamide (NSC 696085) is a potent histone deacetylase inhibitor with an IC50 of 100 nM for HDAC-1. In a study, administration of pyroxamide (100 or 200 mg/kg/day) to nude mice at doses that caused little evident toxicity significantly suppressed the growth of s.c. CWR22 prostate cancer xenografts. Despite the potent growth-inhibitory effects of pyroxamide in this tumor model, serum prostate-specific antigen levels in control versus pyroxamide-treated mice were not significantly different. It causes the accumulation of acetylated core histones in MEL cells cultured with the agent. Human CWR22 prostate tumor xenografts from mice treated with pyroxamide (100 or 200 mg/kg/day) showed increased levels of histone acetylation and increased expression of the cell cycle regulator p21/WAF1, compared with tumors from vehicle-treated control animals.

Chemical Information
Molecular Weight 265.31
Formula C13H19N3O3
CAS Number 382180-17-8
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Jakob Haldrup, et al. FRMD6 has tumor suppressor functions in prostate cancer

[2] Gregory Kouraklis, et al. Histone deacetylase inhibitors: a novel target of anticancer therapy (review)

[3] Martha C Kutko, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro

[4] G Kouraklis, et al. Histone deacetylase inhibitors and anticancer therapy

[5] L M Butler, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase

Related HDAC Products
CM-444

CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models.

CM-1758

CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells.

T-518 

T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6.

SE-7552 

SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM.

BRD9757 

BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pyroxamide, NSC-696085 supplier, HDAC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.